The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
Open accessAbstract
The Raf family includes three members, of which B-Raf is frequently mutated in melanoma and other tumors. We show that Raf-1 and A-Raf require Hsp90 for stability, whereas B-Raf does not. In contrast, mutated, activated B-Raf binds to an Hsp90–cdc37 complex, which is required for its stability and function. Exposure of melanoma cells and tumors to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in the degradation of mutant B-Raf, inhibition of mitogen-activated protein kinase activation and cell proliferation, induction of apoptosis, and antitumor activity. These data suggest that activated mutated B-Raf proteins are incompetent for folding in the absence of Hsp90, thus suggesting that the chaperone is required for the clonal evolution of melanomas and other tumors that depend on this mutation. Hsp90 inhibition represents a therapeutic strategy for the treatment of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Self-citationBRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
Self-citationHSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
Neckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
V599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
An, W. G., Schulte, T. W., & Neckers, L. Μ. (2000) · PubMed · Cited by 267
p50cdc37 Acting in Concert with Hsp90 Is Required for Raf-1 Function
Grammatikakis, N., Lin, J.-H., Grammatikakis, A., Tsichlis, P. N., & Cochran, B. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1661 · Cited by 261
Geldanamycin-Induced Destabilization of Raf-1 Involves the Proteasome
Schulte, T. W., An, W. G., & Neckers, L. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7527 · Cited by 190
Fumo, G., Akin, C., Metcalfe, D. D., & Neckers, L. (2003) · Blood · doi:10.1182/blood-2003-07-2477 · Cited by 149
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
REIFENBERGER, J., Knobbe-Thomsen, C. B., Sterzinger, A. A., Blaschke, B., Schulte, K. W., Ruzicka, T., & Reifenberger, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11722 · Cited by 146
Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2002) · PubMed · Cited by 144
Overview: Translating Hsp90 Biology into Hsp90 Drugs
Workman, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481868 · Cited by 139
MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Sebolt–Leopold, J. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384439 · Cited by 123
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., & Hansson, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20873 · Cited by 110
Nüsse, M., Beisker, W., Hoffmann, C., & Tárnok, A. (1990) · Cytometry · doi:10.1002/cyto.990110707 · Cited by 88
Cited by
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
“Importantly, V600E BRAF is more sensitive to 17AAG than wild-type BRAF, but 17AAG also targets wild-type BRAF and CRAF downstream of oncogenic Ra”
BackgroundPhosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
Junttila, M. R., Li, S., & Westermarck, J. (2008) · The FASEB Journal · doi:10.1096/fj.06-7859rev · Cited by 826
Metadata
- Authors
- Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-12-21
- Volume
- 103
- Issue
- 1
- Pages
- 57-62
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1991196199
- Cited by
- 308
- References
- 31
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.